The Technical AnalystExchange: HKSE Industry: Asset Management
Regent Pacific Group Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% HKD0.400
America/New_York / 28 apr 2024 @ 23:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 91.36 mill |
| EPS: | -0.870 |
| P/E: | -0.460 |
| Earnings Date: | Mar 27, 2024 |
| SharesOutstanding: | 228.39 mill |
| Avg Daily Volume: | 0.0221 mill |
| RATING 2024-04-29 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.460 | sector: PE 16.62 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.460 | industry: PE 19.32 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
HKD 0.377 - 0.423 ( +/- 5.75%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | HKD0.400 (0.00% ) |
| Volume | 0.0586 mill |
| Avg. Vol. | 0.0221 mill |
| % of Avg. Vol | 265.17 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 0575.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
0575.HK
Endurance RP Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in the People's Republic of China, Europe, Hong Kong, and Taiwan. The company operates in two segments, Biopharma and Corporate Investment. It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management and corporate finance services. The company was formerly known as Regent Pacific Group Limited and changed its name to Endurance RP Limited in June 2021. Endurance RP Limited was incorporated in 1991 and is headquartered in Central, Hong Kong.